Clinical Trial Detail

NCT ID NCT02892734
Title Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Northwestern University
Indications

Her2-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST